Reviews
3 June 2025
Early Access
https://doi.org/10.4081/reumatismo.2025.1735

Peripheral neuropathy in antiphospholipid syndrome: a systematic review

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Peripheral neuropathy, antiphospholipid syndrome, thrombosis, thrombophilia, mononeuritis multiplex
14
Views
5
Downloads

Authors

Rafael Reis do Espírito Santos
Faculty of Medicine, Federal University of Pará, Belém-Pará, Brazil.
Cezar Augusto Muniz Caldas
https://orcid.org/0000-0002-1141-1281
Faculty of Medicine, Federal University of Pará, Belém-Pará, Brazil.
Jozélio Freire de Carvalho
jotafc@gmail.com
https://orcid.org/0000-0002-7957-0844
Institute for Health Sciences, Federal University of Bahia, Salvador, Brazil.

Objective. Antiphospholipid syndrome (APS) is a disease characterized by recurrent thrombosis in the presence of antiphospholipid antibodies. The most uncommon events described in the literature have been peripheral neurological disorders. This paper aims to systematically review the cases of peripheral neuropathy (PN) in APS patients.

Methods. We systematically searched articles on PN and APS with English abstracts in PubMed from 1966 to August 2022.

Results. We found 10 articles on PN and APS with 100 patients. Age varied from 25 to 78 years; 86-100% of patients in these studies were female. Most patients had primary APS (n=9); one article considered secondary APS associated with other autoimmune diseases. Disease duration varied from 0 to 8.6 years, but three articles did not provide this information. Most studies showed positivity for anticardiolipin antibodies (n=5), followed by lupus anticoagulant (n=2). Regarding clinical NP features, mononeuritis multiplex (n=3) and autonomic neuropathy (n=3) were more common than peripheral polyneuropathy (n=2). Nerve biopsy was performed in 7 articles and found positivity in all cases. Concerning treatment, most articles used anticoagulation (n=4), followed by glucocorticoids (n=3), intravenous immunoglobulin, and immunosuppressive drugs (n=1). Most cases improved after treatment (n=7).

Conclusions. This study demonstrates that PN is a rare complication in APS and occurs more frequently in females, associated with antiphospholipid antibody positivity. Most cases were confirmed by electroneurography or nerve biopsy and had a good outcome.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Sammaritano LR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2020; 34: 101463. DOI: https://doi.org/10.1016/j.berh.2019.101463
Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death: a prospective cohort study. Stroke 1997; 28: 1660-5. DOI: https://doi.org/10.1161/01.STR.28.9.1660
Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010; 40: 350-9. DOI: https://doi.org/10.1111/j.1365-2362.2010.02263.x
Santos MS, de Carvalho JF, Brotto M, Bonfa E, Rocha FA. Peripheral neuropathy in patients with primary antiphospholipid (Hughes') syndrome. Lupus 2010; 19: 583-90. DOI: https://doi.org/10.1177/0961203309354541
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023; 82: 1258-70. DOI: https://doi.org/10.1136/ard-2023-224609
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. DOI: https://doi.org/10.1136/bmj.n71
Schofield JR. Autonomic neuropathy-in its many guises-as the initial manifestation of the antiphospholipid syndrome. Immunol Res 2017; 65: 532-42. DOI: https://doi.org/10.1007/s12026-016-8889-4
Giorli E, Franciotta D, Serventi A, Binda GA, Canepa G, Siciliano G, et al. Sacral nerve stimulation for fecal incontinence in a patient with antiphospholipid syndrome-related autonomic neuropathy. Muscle Nerve 2016; 53: 992-4. DOI: https://doi.org/10.1002/mus.25019
Takahashi M, Katada F, Sato S, Shibayama H, Fukutake T, Murayama S. Mononeuritis multiplex due to thrombotic ischemia of primary antiphospholipid antibody syndrome without vasculitis: an autopsy case report. Rinsho Shinkeigaku 2015; 55: 897-903. [Article in Japanese]. DOI: https://doi.org/10.5692/clinicalneurol.cn-000715
Schofield JR, Blitshteyn S, Shoenfeld Y, Hughes GR. Postural tachycardia syndrome (POTS) and other autonomic disorders in antiphospholipid (Hughes) syndrome (APS). Lupus 2014; 23: 697-702. DOI: https://doi.org/10.1177/0961203314524468
Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol 2013; 12: 172-5.
Bilora F, Biasiolo M, Zancan A, Zanon E, Veronese F, Manca F, Sartori MT. Autonomic dysfunction and primary antiphospholipid syndrome: a frequent and frightening correlation? Int J Gen Med 2012; 5: 339-43. DOI: https://doi.org/10.2147/IJGM.S29822
Rodrigues CE, Carvalho JF. Multiple mononeuropathy secondary to thrombosis of the vasa nervorum in primary antiphospholipid syndrome. Isr Med Assoc J 2010; 12: 448-9.
Jeruc J, Popovic M, Vizjak A, Jurcić V, Lestan B, Ferluga D. Multiple mononeuropathy due to vasculitis associated with anticardiolipin antibodies: a case report. Folia Neuropathol 2006; 44: 140-3.
Erten N, Saka B, Karan MA, Parman Y, Umman B, Tascioglu C. Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report. Acta Med Okayama 2004; 58: 107-10.
Sanna G, D’Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am 2006; 32: 465-90. DOI: https://doi.org/10.1016/j.rdc.2006.05.010
Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003; 12: 903-7. DOI: https://doi.org/10.1191/0961203303lu500oa
Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Peripheral nervous system disease in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol 2020; 72: 67-77. DOI: https://doi.org/10.1002/art.41070
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11. DOI: https://doi.org/10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306. DOI: https://doi.org/10.1111/j.1538-7836.2006.01753.x

How to Cite



Peripheral neuropathy in antiphospholipid syndrome: a systematic review. (2025). Reumatismo. https://doi.org/10.4081/reumatismo.2025.1735
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.